CEO
CTO
Chief Scientific Officer
CFO
Director of Research and Development
Head of Commercial
Scientist
Scientist
CEO
CTO
CFO
Rational Design. Supercharged.
© Copyright 2024 Immuto Therapeutics. All rights reserved.
President and CEO
Immuto Scientific Inc.
Faraz A. Choudhury, PhD is the President and CEO of Immuto Scientific. Dr. Choudhury co-founded Immuto Scientific in 2018. As the CEO, he defined the vision and strategy, contributed to core inventions, and is currently responsible for the operations and management of the company. Dr. Choudhury co-invented Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology and he has been involved in the design, development and application of the technology from the inception. His doctorate research work focused on developing plasma technologies for semiconductor manufacturing as well as biological applications. After completing his postdoctoral training, he spent several years as a Research Scientist in the Department of Biochemistry at the University of Wisconsin- Madison (UW Madison). His research focused on proteomics, epitope mapping and protein-protein interactions studies using mass spectrometry. Dr. Choudhury served as a Principal Investigator (PI) on two grants and has been involved as co-investigator or contributor to several other grants from NIH, NSF, NIFA, WARF and WEDC totaling over $1.4M. He administered the projects, developed research plans, collaborated with other researchers, and produced several peer-reviewed publications and two patents.
Education & Credentials
Post Doctorate: University of Wisconsin- Madison
Ph.D., University of Wisconsin- Madison
B.A., Lawrence University
Chief Scientific Officer
Neal Goodwin is our Chief Scientific Officer responsible for Immuto translational drug discovery programs. With over 20 years of experience in drug discovery and development, Neal has contributed to successful IPOs, multiple technology deals, and award-winning research projects. Neal’s core competencies include advanced translational platforms, drug discovery and development, and gene delivery technologies. Neal is a founder of Jaya Biosciences, developing gene therapies for neurodegenerative diseases, including Alzheimer’s disease. Neal is the past CSO for Teknova (NASDAQ: TKNO), where he implemented gene-delivery technology platforms. Before Teknova, Neal was Vice President of Corporate Research Development for Champions Oncology (NASDAQ: CSBR), developing a personalized and translational oncology pharmacology platform. Before Champions, Neal served as the Director of Research and Development and Program Director of JAX Cancer Services, where he established an oncology translational tumor biology program in collaboration with over 20 clinical trial centers. Neal is a co-founder and former CSO of ProNAi Therapeutics (Sierra Oncology; NASDAQ: SRRA; acquired by GSK). Neal received a Ph.D. in Microbiology from The University of Montana and served an NIH postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).
CTOImmuto Scientific Inc.
Dr. Benjamin is the Chief Technology Officer and co-founder of Immuto Scientific. As the CTO, Dr. Benjamin is responsible for leveraging Immuto’s technological resources and expertise to meet the needs of our customers. As one of the inventors of Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology, Dr. Benjamin spearheaded the design, development, and engineering of the technology. His doctorate research work focused on development the PLIMB technology and proving its application for applications relevant to biopharmaceutical research.
Education & Credentials
Ph.D., University of Wisconsin – Madison
M.S., University of Wisconsin – Madison
B.A., University of Wisconsin – Madison
CFO
Brad Chandler is a Board Member and Chief Financial Officer of Immuto Scientific. Prior to Immuto, Brad was a Managing Director in the Investment Banking Division of Morgan Stanley in New York City. Brad is also the Director of the Nicholas Center for Corporate Finance and Investment Banking at the Wisconsin School of Business. Brad holds a JD from the University of Chicago Law School, an MBA from the University of Chicago Booth School of Business and a BA from Duke University.
Scientific Director
Dr. Dowell is the Scientific Director of Immuto Scientific. In this role, Dr. Dowell oversees all research and development activities related to structural biology, biochemistry, and mass spectrometry. Dr. Dowell has more than 15 years of combined research experience in academia and the pharmaceutical industry. He is an expert in proteomics, neurobiology, and epigenetics. He was previously a senior scientist at Arrowhead Pharmaceuticals with extensive experience in pharmacokinetics and drug development. He holds a doctorate in Pharmaceutical Sciences from the University of Wisconsin-Madison and has more than 20 scientific publications.
Head of Commercial
Dr. Hetal Marble is Head of Commercial for Immuto Scientific, a boutique CRO focused on protein structural characterization and drug discovery.
Dr. Marble has had varied and extensive experience leading life science businesses. She led diagnostic product management at Quanterix Corporation, where she launched Quanterix’s first diagnostic test for Alzheimer’s disease and directed product strategy and go-to-market for all clinical diagnostic and research services products. She also led companion diagnostics and biomarker development for the Center for Integrated Diagnostics at MGH where she grew the division’s in-house CRO into a multi-million dollar enterprise by translating novel technologies into clinical practice and leading precision biomarker strategies for clinical trials. Prior to her work at MGH, Hetal worked in business development,alliance management, and strategic product marketing for both Promega Corporation and Pall Biotech (a Danaher company), managing and growing burgeoning commercial territories into millions of dollars in revenue. Hetal is foundationally an experienced research scientist – she received her Ph.D. at Brown University, where her graduate work focused on development of biomarkers for lineage-specific stem cell differentiation - she is the holder of two U.S. patents emerging from that work. Hetal is active in the scientific community; she is the elected Chair of Diversity, Equity, and Inclusion for the Association for Molecular Pathology (AMP); she is a member of the 2022 Women in Bio (WiB) cohort of Emerging Executives; she served on the Pathology Informatics Collaborative Community (PIcc), a collaborative community of the US Food and Drug Administration; and she is a contributing author on precision medicine for the book Taking Care of You, a book on women’s health being published by the Mayo Clinic Press in October 2022.
Matt is a co-manager at Wisconsin Investment Partners (WIP). Matt brings four years of experience as a major project finance attorney at Milbank, Tweed, Hadley & McCloy, LLP, one of the world’s leading law firms. He graduated cum laude from American University, Washington College of Law, where he served as Senior Note & Comment Editor on the Social Policy law journal. In addition to his law degree, Matt has a B.S. in Biochemistry and History from the University of Wisconsin-Madison.
Greg is a Senior Director of Ventures & Accelerator at WARF. He has a M.S.E. Management of Technology from University of Pennsylvania with more than 20 years technology commercialization experience, including leadership positions in Fortune 500, startup and small-cap public companies.
St John is VP of Marketing and Product Strategy at protein Metrics, Inc. (PMI) which is one of the leading Mass Spec Software solutions providers. He joined Protein Metrics as a startup and has led the sales and marketing efforts since 2015, with growth at triple and double-digit levels from the outset. Until August 2021 he was VP of Sales and Support.
Before joining PMI, he was Senior Manager, Global Markets, Biologics at Sciex (Danaher) providing business insight, sales training, and product development direction for the Pharmaceutical business unit. He had previously been at Waters as a Senior Market Manager for Biopharma, leading a team of technical marketing experts. Prior to that he was in Sales leadership positions, worldwide. His experience in sales, marketing, business development, and analyst roles has helped provide a rounded view of product portfolios and how to deliver tools that are meaningful for customers.
St John studied Chemical Engineering and Chemistry at the University of Cape Town, and has a PhD from the University of Fribourg.
CTO
Immuto Scientific Inc.
Dr. Benjamin is the Chief Technology Officer and co-founder of Immuto Scientific. As the CTO, Dr. Benjamin is responsible for leveraging Immuto’s technological resources and expertise to meet the needs of our customers. As one of the inventors of Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology, Dr. Benjamin spearheaded the design, development, and engineering of the technology. His doctorate research work focused on development the PLIMB technology and proving its application for applications relevant to biopharmaceutical research.
Education & Credentials
Ph.D., University of Wisconsin – Madison
M.S., University of Wisconsin – Madison
B.A., University of Wisconsin – Madison